TY - JOUR
T1 - Chronic myeloid leukaemia - The choice of therapy and future perspectives
AU - Carella, Angelo M.
AU - Dellepiane, Clara
AU - Lovera, Davide
AU - Ibatici, Adalberto
AU - Ghiggi, Chiara
AU - Carella, Andrea
AU - Beltrami, Germana
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.
AB - Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.
KW - Chronic myeloid leukaemia
KW - New therapeutic strategies
KW - Stem cell biology
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84973652216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973652216&partnerID=8YFLogxK
U2 - 10.17925/EOH.2015.11.01.25
DO - 10.17925/EOH.2015.11.01.25
M3 - Article
AN - SCOPUS:84973652216
VL - 11
SP - 25
EP - 29
JO - European Oncology and Haematology
JF - European Oncology and Haematology
SN - 2045-5275
IS - 1
ER -